Figure 3, Part B continued

Agent[1]	Status of Vaccine Development					Status of Licensure		Status of Immunization						
	Vaccine Research and Development		Safety and Efficacy Testing			Licensure		Estimated Covera of Target ulation When Recommended (%)						
	Basic R&D	Animal Models	Phase I	Phase II	Phase III	Application Made	License Granted	Target	0-20	20-40	40-60	60-80	80-100	Eradication
Legionella pneumophila														
Leishmania sp.														
Mycobacterium leprae														
Mycoplasma pneumoniae														
Neisseria gonorrheae														
Neisseria meningitidis B														
Parainfluenza virus														
Plasmodium spp. (malaria)														
Pseudomonas sp.														
Respiratory syncytial virus														
Rickettsia rickettsii														
Rotavirus														
Schistosoma mansoni														
Shigella														
Toxoplasma gondii														
Treponema pallidum														
Varicella virus														
Venezuelan equine encephalitis, eastern equine encephalitis, and western equine encephalitis viruses														

Source: NIAID data.

[1]For a description of the diseases that these agents cause see "The Jordan Report: Accelerated Development of Vaccines -- 1993 (National Institute of Allergy and Infectious Diseases, 1993).